课题基金 / 基金详情

MECHANISMS OF IMMUNOLOGIC TOLERANCE AND ITS BREAKDOWN

MECHANISMS OF IMMUNOLOGIC TOLERANCE AND ITS BREAKDOWN
免疫耐受及其分解机制
批准号:
6076550
负责人:
David William Scott
金额:
$0.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-03-01 至 2001-02-28

项目摘要

项目成果

David William Scott的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (adapted from the applicant s application): The establishment of immunologic tolerance is one of the fundamental tenets of immunology and one of the most active areas of research. Understanding the mechanisms of self- nonself discrimination in tolerance and its breakdown in autoimmunity are at the cutting edge for developing new therapies in the treatment of immunologic diseases, such as diabetes, lupus and multiple sclerosis. Currently, transgenic models for tolerance, using mice with rearranged T- and B-cell receptors and expressing peptides or antigens under the control of different promoters, provide novel insights into tolerance mechanisms. Examination of the fate of tolerant (e.g., anergic) cells in the periphery has also been facilitated by such models. Moreover, these models, as well as the use of cloned T- and B-cell lines or lymphomas, are providing exciting approaches to understanding the signals for anergy versus apoptosis in the immune system. This meeting will address the mechanisms of immunologic tolerance and its breakdown in autoimmunity, as well as novel therapies, by promoting the interaction of basic and clinical researchers in diverse fields. It will be of great interest also to biotech scientists, as well as post-doctoral fellows.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bispecific antibody to target FVIII-specific B cells
  • 批准号:
    10598041
  • 项目类别:
  • 资助金额:
    $18.26万
  • 财政年份:
    2022
  • 负责人:
    David William Scott
  • 依托单位:
Bispecific antibody to target FVIII-specific B cells
  • 批准号:
    10365461
  • 项目类别:
  • 资助金额:
    $21.92万
  • 财政年份:
    2022
  • 负责人:
    David William Scott
  • 依托单位:
Engineering Specific Regulatory T Cells to Treat Allergy
Engineered CARs Targeting FVIII-specific T and B Cells
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: